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Recently, variants in CHEK2 gene were shown to associate with sporadic prostate cancer in the USA. In the present study from
Finland, we found that the frequency of 1100delC, a truncating variant that abrogates the kinase activity, was significantly elevated
among 120 patients with hereditary prostate cancer (HPC) (four out of 120 (3.3%); odds ratio 8.24; 95% confidence interval 1.49–
45.54; P¼0.02) compared to 480 population controls. Suggestive evidence of segregation between the 1100delC mutation and
prostate cancer was seen in all positive families. In addition, I157T variant had significantly higher frequency among HPC patients (13
out of 120 (10.8%); odds ratio 2.12; 95% confidence interval 1.06–4.27; P¼0.04) than the frequency 5.4% seen in the population
controls. The results suggest that CHEK2 variants are low-penetrance prostate cancer predisposition alleles that contribute
significantly to familial clustering of prostate cancer at the population level.
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Analyses using families with hereditary prostate cancer (HPC)
have suggested that multiple genetic loci may harbour prostate
cancer susceptibility genes, including HPC1 (MIM 601518) at
1q24–q25, HPC2 (MIM 605367) at 17p11, PCAP (MIM 602759) at
1q42–q43, HPCX (MIM 300147) at Xq27–q28, CAPB (MIM
603688) at 1p36, and HPC20 (MIM 176807) at 20q13 (Nwosu
et al, 2001). So far, only two genes have been identified from these
chromosomal regions: ELAC2 from HPC2 –locus (Tavtigian et al,
2001) and RNASEL (MIM 180435) from HPC1 –locus (Carpten
et al, 2002). In Finland neither ELAC2 nor RNASEL did explain the
disease segregation in HPC families, but seemed to have some kind
of modifying role in prostate carcinogenesis (Rokman et al, 2001;
Rokman et al, 2002). Xu et al (2001) identified a new locus at
8p22–23, and mutations in MSR1 gene (MIM 153622) were
reported to associate with prostate cancer (Xu et al, 2002).
However, recent results do not support a major role for the MSR1
gene in the causation of prostate cancer (Seppala et al, in press).
Definitive confirmations of the role of ELAC2, RNASEL,o rMSR1
in prostate cancer predisposition are still warranted.
Recently, mutations in CHEK2 (MIM 604373) were identified in
patients with prostate cancer (Dong et al, 2003). The CHEK2 gene
localises to chromosome 22q12.1 and contains 14 exons.
Originally, germline mutations in CHEK2 gene were reported in
Li–Fraumeni syndrome and breast cancer (Bell et al, 1999; Allinen
et al, 2001). Rare somatic mutations in CHEK2 have also been
identified in a number of cancer types, including lung and ovarian
cancers and osteosarcomas (Miller et al, 2002). These results
together with the normal function of CHEK2 in DNA damage
checkpoints are consistent with the idea that CHEK2 might act as a
tumour suppressor gene. Here, we explored the significance of
CHEK2 gene in prostate cancer causation in Finland. The Finnish
population is known to be historically isolated and genetically
homogeneous (Peltonen et al, 2000). Therefore, there may be a
limited number of prostate cancer causing mutations, and the
effect of individual risk genes could be identified more readily than
in more heterogeneous populations.
MATERIALS AND METHODS
Families with HPC
Collection of Finnish families with HPC has been described
elsewhere (Schleutker et al, 2000). For single-strand conformation
polymorphism (SSCP) analysis, youngest affected patient from
each of the 120 HPC families was initially used for the screening of
CHEK2 mutations. The HPC families consisted of two cohorts. The
families in the first cohort (n¼68) had either three or more first-
or second-degree- affected members or two affected members with
at least the index patient diagnosed with prostate cancer p60
years of age. The mean age at diagnosis for the index patients was
62.2 years (range 44–81 years), and the mean number of affected
family members was 3.2 (range 2–6). The second cohort of
families (n¼52) had only two first- or second-degree affected
members with ages at diagnosis 460 years. The mean age at
diagnosis for the index patients was 69.0 years (range 61–86).
Patients with prostate cancer and controls
The 1100delC and I157T variants were analysed in 537 patients
with unselected prostate cancer, and in 480 healthy male blood
donors. There were altogether 634 consecutive patients diagnosed
with prostate cancer in the Pirkanmaa Hospital District with a
population of around 450000 during 1999–2000. We had samples
from 85% of these patients, which results in an unselected,
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spopulation-based collection of patients. The mean age at diagnosis
for the patients with unselected prostate cancer was 68.6 years
(range 47–90). Information was available on the tumour WHO-
grade in 96%, on Gleason score in 88%, on T-stage in 100%, and on
N-stage in 30% of the patients. M-stage was ascertained by bone
scan in 73% of the patients with PSAX10mgl
 1 and in 26% of the
patients with PSAo10mgl
 1. In all, 12% (66 out of 537) of the
patients reported a positive family history of prostate cancer. The
controls consisted of DNA samples from anonymous male blood
donors obtained from the Blood Center of the Finnish Red Cross in
Tampere.
Written informed consent was obtained from all living patients
and also, for families with HPC, from the unaffected members. The
research protocols were approved by the Ethical Committee of the
Tampere University Hospital (93175, 95062, and 99228), and the
National Human Genome Research Institute (HG-0158). Permis-
sion for collection of families, in the entirety of Finland, was
granted by the Ministry of Health and Social Affairs (59/08/95).
Mutation screening with SSCP analysis
Single-strand conformation polymorphism analysis of the entire
coding sequence of the CHEK2 gene was designed to include all
intron–exon boundaries (GenBank accession number AF086904).
Primers used for amplification of exons 10–14, which are known
to be repeated on several other chromosomes (Sodha et al, 2000),
were designed so that both primers for each primer pair had a base
mismatch in the most 30 nucleotide, compared with sequences
from nonfunctional copies of CHEK2. Genomic DNA was used at
25ng per 15ml reaction mixture containing 1.5mM MgCl2;
20mM each of dNTP; 0.5mCi of a(
33P)-dCTP (Amersham Pharma-
cia, Uppsala, Sweden); 0.6mM of each primer; 1.0U AmpliTaqGold;
and the reaction buffer provided by the supplier (PE Biosystems,
Foster City, CA, USA). Annealing temperature of 501C (for exons
10 and 12) or 551C (for all other exons) was used. After
denaturation, the (
33P)-labeled PCR products were electrophoresed
at 800V for 12h at room temperature, in 0.5  mutation-
detection-enhancement gel (FMC BioProducts, Rockland, ME,
USA) with 1% glycerol in 0.5  Tris-borate EDTA. For exon 11, the
electrophoresis was also performed without glycerol in the gel.
After electrophoresis, gels were dried and exposed to Kodak
BioMax maximum-resolution films for 6h. All samples, in which
variant bands were detected, as well as two normal bands per exon,
were sequenced using the same PCR primers and ABI Prism 310
Genetic Analyzer (PE Biosystems, Foster City, CA, USA). Also, the
genotypes of the available family members of the mutation carriers
were determined by sequencing.
Minisequencing and SSCP for large-scale population
screening of identified variants
The frequencies of the two CHEK2 variants were determined in the
entire sample of patients described above. 1100delC variant was
screened by minisequencing (Syvanen, 1998). PCR was performed
with 100ng of DNA, 0.2mM each primer, 0.2mM each dNTP, 1.5mM
MgCl2, and 1.0U of AmpliTaqGold (PE Biosystems, Foster City,
CA, USA), in a final volume of 50ml. I157T variant was screened by
SSCP analysis as described above. Positive results from both
mutation analyses were confirmed by sequencing.
Statistical analyses
Association of the CHEK2 genotypes with HPC and unselected
prostate cancer was tested by logistic-regression analysis, by use of
the SPSS statistical software package (SPSS 11.0). Association with
demographic, clinical, and pathological features of the disease was
tested by the Mann–Whitney test, Pearson w
2 test, and Fisher’s exact
test by use of the SPSS statistical software package (SPSS 11.0).
RESULTS
Five sequence variants were identified in the SSCP analysis of the
CHEK2 gene in 120 index patients from Finnish families with HPC
(Table 1). Two of the variants, a missense variant 470T4C (I157T)
in exon 3 and a frameshift mutation 1100delC in exon 10, were the
same as previously reported in patients with Li–Fraumeni
syndrome (Bell et al, 1999), breast (Allinen et al, 2001; Vahteristo
et al, 2002), and prostate cancer (Dong et al, 2003). The frameshift
1100delC mutation has been proven to result in the loss of kinase
activity (Wu et al, 2001), and I157T variant has been shown to be
defective in its ability to bind and phosphorylate Cdc25A, one of
its normal substrates (Falck et al, 2001). These variants were
further studied in a set of 1137 samples. In addition, a silent exonic
change also reported by Bell et al (1999), an intronic change (not
affecting splice site), and a novel missense mutation 1312G4T
(D438Y) were observed. D438Y mutation was found only in one
proband. In this family there were two prostate cancer patients.
Unfortunately, we did not have a sample from the second affected
person (deceased).
The 120 patients with HPC included 3.3% (four out of 120)
patients who carried the 1100delC mutation (Table 2). This was
significantly higher (odds ratio (OR)¼8.24; 95% confidence
interval (CI) 1.49 45.54; P¼0.02) than the frequency 0.4% seen
in population sample of 480 blood donors. Among the unselected
patients with prostate cancer, the frequency of 1100delC variant
was 1.3% (seven out of 537). All 1100delC carriers were
heterozygous. All other affected and unaffected male relatives
were also genotyped from 1100delC-positive families. Suggestive
evidence of segregation between the 1100delC mutation and
prostate cancer was seen in all four families (Figure 1). Since
1100delC mutation has been reported in Li–Fraumeni syndrome
and was previously called a mutation hot spot (CHEK2 [MIM
604373]), we looked other cancers in these four 1100delC-positive
families. In family 001, there was one second-degree relative
diagnosed with lung cancer, but no other cancers were found
among first- or second-degree relatives.
Table 1 Summary of CHEK2 germline variants found in 120 patients
with HPC in the SSCP analysis
Mutation Amino-acid change Exon/intron Domain
252A4G Silent (E84) Exon 1 Unknown
319+(43 44)insA — Intron1 —
470T4C I157T Exon 3 FHA
a
1100delC Frameshift Exon 10 Kinase
1312G4T D438Y Exon 11 Kinase
aFHA¼forkhead-associated domain.
Table 2 Association of the 1100delC and I157T variants of the CHEK2
gene with patients with unselected prostate cancer or HPC
Mutation and sample
No. of carriers/total
(frequency) OR 95% CI P
1100delC
Controls 2/480 (0.4%) 1.00
Patients with unselected
Prostate cancer
7/537 (1.3%) 3.14 0.65 15.16 0.15
Patients with HPC 4/120 (3.3%) 8.24 1.49 45.54 0.02
a
I157T
Controls 26/480 (5.4%) 1.00
Patients with unselected
Prostate cancer
42/537 (7.8%) 1.48 0.89 2.46 0.13
Patients with HPC 13/120 (10.8%) 2.12 1.06 4.27 0.04
a
aStatistically significant.
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sThe I157T variant was seen in 10.8% (13 out of 120) of patients
with HPC (Table 2). This was also significantly higher (OR¼2.12;
95% CI 1.06 4.27; P¼0.04) than the frequency of 5.4% seen in the
population controls. Nine of the I157T-positive families had only
two affecteds, three families had three affecteds, and one family
had four affecteds. Segregation of the variant with the disease was
incomplete, in that both unaffected mutation carriers and
mutation-negative patients with prostate cancer were observed.
In addition, the I157T variant was found in 7.8% (42 out of 537) of
unselected prostate cancer patients. One of these carriers was
homozygous; all other I157T variant carriers were heterozygous.
The homozygous carrier did not have family history of cancer and
there was nothing unusual in his phenotype. None of the patients
or controls carried both 1100delC and I157T variant.
The mean ages at diagnosis of the CHEK2 variant carriers in
patients with HPC were 62.7 years for 1100delC carriers and 64.0
years for I157T carriers. These ages were only marginally different
from the mean age of HPC patients with no mutations (65.2 years
for both variants; P¼0.57 for 1100delC and P¼0.62 for I157T). A
similar trend was observed in the cohort of unselected prostate
cancer patients (64.6 vs 68.7 years; P¼0.18 for 1100delC and 68.4
vs 68.6 years; P¼0.86 for I157T). The association between the
frequency of the two variants and disease phenotype, including
tumour WHO-grade, Gleason score, T-, N- and M-stage and PSA
value at diagnosis, were also analysed among unselected prostate
cancer cases. No significant associations emerged from these
analyses (data not shown).
DISCUSSION
CHEK2 has been suggested to be a candidate tumour suppressor
gene on the basis of the findings that normal function of CHEK2 is
involved in DNA-damage respond and some of the mutations
identified in Li–Fraumeni families were expected to result in a
truncated protein (Bell et al, 1999). Subsequently, these findings
were supported by the reports concerning identical and additional
mutations in patients with Li–Fraumeni syndrome (Lee et al,
2001) and breast cancer (Meijers-Heijboer et al, 2002; Vahteristo
et al, 2002). While this manuscript was in preparation, another
study was published showing that mutations in CHEK2 were
associated also with prostate cancer risk (Dong et al, 2003).
Our results suggest that CHEK2 1100delC mutation is associated
with positive family history of prostate cancer. The mutation
segregated almost completely in all mutation-positive families
(Figure 1). In family 351, there were three unaffected men, who
carried the variant. Two of them were rather young, about 50 years
old (III-2 and III-3), and the third unaffected carrier was 71 years
old (II-5). The total PSA values of the unaffected mutation carriers
of this family were measured in July 2000. The values were o0.5,
2.2, and 2.4mgl
 1 for III-2, III-3 and II-5, respectively. The mean
age at diagnosis of prostate cancer in Finland was 71.1 years in
1999 (Finnish Cancer Registry; cancer statistics at http://www.can-
cerregistry.fi/) and all three affecteds of the family 351 were over 66
years old when diagnosed for prostate cancer, thus the future
diagnosis of prostate cancer cannot be ruled out for the healthy
carriers of this family. On the other hand, in the four 1100delC-
positive families, there were no mutation-negative prostate cancer
patients. The association of 1100delC mutation with families that
include small number of affected relatives, the most common types
of prostate cancer families, implies that the mutation is likely to
have a significant contribution to familial prostate cancer at the
population level. In addition, I157T seems to be a disease-
associated polymorphism at least in the Finnish population. It has
a slightly higher frequency among patients with unselected
prostate cancer than among control individuals and it is strongly
associated with family history of the disease. However, according
to the previous reports, the I157T allele does not make a significant
contribution to breast cancer susceptibility (Allinen et al, 2001;
Schutte et al, 2003). Therefore, the association with this allele is
less conclusive.
Previously, Vahteristo et al (2002) reported the strong associa-
tion of the CHEK2 1100delC with breast cancer families that
included only two affected patients, suggesting that 1100delC is a
low-penetrance genetic alteration. In contrast to our results, Dong
et al (2003) reported the association of the CHEK2 mutations (all
mutations pooled together) only with sporadic prostate cancer. In
addition, they did not observe any association between prostate
cancer and I157T variant. The reason why Dong et al (2003) did
not detect any association with HPC could be due to different
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Figure 1 Segregation of CHEK2 1100delC mutation in four families with
HPC. 1100delC variant carriers are denoted by a plus sign (þ), and
noncarriers by a minus sign ( ). An asterisk (*) denotes the persons with
no sample available. No sample was available from affected father (II-2) in
family 351, but because the mother (II-1) did not carry the mutation, the
father is a likely 1100delC mutation carrier. Current age of the unaffected
members or age at diagnosis for prostate cancer patients (in years) is
indicated below the symbol for each family member. In each family, the
index patient is marked with an arrow. Squares denote male subjects, and
circles denote female subjects; black symbols denote patients with prostate
cancer.
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ssample settings: the families from the USA represent more extreme
HPC families than the Finnish families in the present study.
In their study two affected members from 149 HPC families with
at minimum of three affected men over at least two generations
were used. In our recent genome-wide linkage analysis, no positive
signals were seen on chromosome 22 (Schleutker et al, in press).
This is probably due to the selected study material, as only
the most extreme families were genotyped, possibly reflecting the
same phenomenon as seen in the study of Dong et al (2003). Also,
the low allele frequencies of CHEK2 variants (o10%) make this
kind of an association almost impossible to detect by linkage
analysis.
Dong et al (2003) reported a total of 13 different
CHEK2 germline mutations among 400 sporadic prostate
cancer patients and 298 individuals with familial prostate cancer.
Most of these mutations occurred only once in their study
population. The reason why fewer variants were found in our
study can possibly be due to the limited sensitivity of the
SSCP analysis and the number of screened patients. Most likely,
however, the reason is the study population itself. The Finnish
population is genetically much more homogeneous than the US
population, and therefore it is not surprising that fewer variants
were detected.
Taken together, finding of the 1100delC and I157T variants in
families with small numbers of affected relatives support the idea
that CHEK2 variants are low-penetrance prostate cancer predis-
position alleles that contribute significantly to familial clustering of
prostate cancer at the population level, especially in families with
small number of affected relatives. However, variants in CHEK2
gene alone do not explain the familial clustering of prostate cancer
in Finland as the majority of families did not have any CHEK2
alterations. The present results warrant further studies of the role
of CHEK2 variants as a risk factor for prostate cancer in other
populations.
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